Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970973 | 0.90 | TSHR (0.59) | TSHRMAPK1ALDH1A1LMNAPGR | |
| SCHEMBL6979105 | 0.87 | CYP1A2 (0.52) | TSHRTP53QPCTMAPTGAA | |
| SCHEMBL6977516 | 0.87 | PGR (0.58) | TSHRMAPK1ALDH1A1PGRQPCT | |
| SCHEMBL6981540 | 0.86 | TSHR (0.47) | TSHRPGRQPCTGSK3BGAA | |
| SCHEMBL6979415 | 0.86 | TSHR (0.49) | TSHRPGRQPCTCYP19A1GAA | |
| SCHEMBL6979316 | 0.86 | TSHR (0.47) | TSHRMAPK1ALDH1A1PGRQPCT | |
| SCHEMBL6979770 | 0.84 | FNTA (0.46) | TSHRLMNAPGRQPCTCYP19A1 | |
| SCHEMBL6976681 | 0.84 | ALDH1A1 (0.46) | TSHRALDH1A1LMNAPGRQPCT | |
| SCHEMBL6979646 | 0.84 | TSHR (0.52) | TSHRMAPK1ALDH1A1PGRQPCT | |
| SCHEMBL6979210 | 0.83 | PDE4A (0.55) | TSHRALDH1A1PGRTP53QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | TSHR 3090/4885MAPK1 914/4885ALDH1A1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.